Difficulty: Medium
Average Score: 86%
Practice
Which one of the following agents acts at the step of antigen recognition?
Correct answer
D
Rationale
In the context of ABVD chemotherapy drugs, the correct answer to the question asking which agent acts at the step of antigen recognition is D) Rh0 (D) immune globulin.
Rh0 (D) immune globulin, also known as RhoGAM, is used to prevent an immune response to Rh positive blood in people with an Rh negative blood type. In the context of ABVD chemotherapy, it is used to prevent a reaction that could occur when an Rh negative individual is exposed to Rh positive blood during treatment. This immune globulin acts at the step of antigen recognition by binding to the Rh antigen on red blood cells, thus preventing the immune system from recognizing and mounting a response against these foreign antigens.
Now, let's discuss why the other options are incorrect:
A) Cyclosporine: Cyclosporine is an immunosuppressant drug that works by inhibiting T-cell activation and is commonly used to prevent organ rejection after transplants. It does not act at the step of antigen recognition like Rh0 (D) immune globulin does.
B) Cyclophosphamide: Cyclophosphamide is a chemotherapy drug that works by interfering with the growth of cancer cells. It does not directly act at the step of antigen recognition.
C) Methotrexate: Methotrexate is another chemotherapy drug that works by inhibiting dihydrofolate reductase, thus interfering with DNA synthesis and cell replication. It does not act at the step of antigen recognition like Rh0 (D) immune globulin does.
In an educational context, understanding how different drugs work at specific steps in processes such as antigen recognition is crucial for healthcare professionals to make informed decisions about treatment strategies and patient care. This knowledge helps in optimizing treatment outcomes and minimizing potential adverse effects.
Rh0 (D) immune globulin, also known as RhoGAM, is used to prevent an immune response to Rh positive blood in people with an Rh negative blood type. In the context of ABVD chemotherapy, it is used to prevent a reaction that could occur when an Rh negative individual is exposed to Rh positive blood during treatment. This immune globulin acts at the step of antigen recognition by binding to the Rh antigen on red blood cells, thus preventing the immune system from recognizing and mounting a response against these foreign antigens.
Now, let's discuss why the other options are incorrect:
A) Cyclosporine: Cyclosporine is an immunosuppressant drug that works by inhibiting T-cell activation and is commonly used to prevent organ rejection after transplants. It does not act at the step of antigen recognition like Rh0 (D) immune globulin does.
B) Cyclophosphamide: Cyclophosphamide is a chemotherapy drug that works by interfering with the growth of cancer cells. It does not directly act at the step of antigen recognition.
C) Methotrexate: Methotrexate is another chemotherapy drug that works by inhibiting dihydrofolate reductase, thus interfering with DNA synthesis and cell replication. It does not act at the step of antigen recognition like Rh0 (D) immune globulin does.
In an educational context, understanding how different drugs work at specific steps in processes such as antigen recognition is crucial for healthcare professionals to make informed decisions about treatment strategies and patient care. This knowledge helps in optimizing treatment outcomes and minimizing potential adverse effects.